Physician profile
Lindsay Rachel Sales
NPI 1720248040
$942.18
in general payments reported to CMS, 2019-2025
26 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Therapeutic Radiology provider received nationally (typical 2025 total: $179).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2020: $196 · 2021: $245 · 2022: $51.67 · 2023: $94.88 · 2024: $93.36 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $341.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $291.78 | 2020-2022 | |
| Janssen Biotech, INC. | $119.13 | 2019-2025 | Erleada |
| Accord Healthcare, INC. | $49.68 | 2024-2025 | |
| Dendreon Pharmaceuticals LLC | $36.55 | 2023 | Provenge |
| Merck Sharp & Dohme LLC | $34.21 | 2024 | Keytruda, Lynparza |
| Amgen INC. | $34.03 | 2020-2021 | |
| Adaptive Biotechnologies Corporation | $25.36 | 2024 | Clonoseq |
| Pharmacyclics LLC, An Abbvie Company | $25.20 | 2023 | Imbruvica |
| Pfizer INC. | $25.05 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $24.92 | 2021 | |
| Daiichi Sankyo INC. | $22.14 | 2020 | |
| Recordati_rare_diseases_inc. | $21.24 | 2025 | Enjaymo |
| Bayer Healthcare Pharmaceuticals INC. | $20.28 | 2023 | |
| Siemens Medical Solutions USA, INC. | $20.23 | 2021 | |
| Abbvie INC. | $19.72 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioprotect Medical, INC. | $18.93 | 2025 | Bioprotect Balloon Implant System |
| Helsinn Therapeutics (U.S.), INC. | $17.35 | 2019 | |
| Sun Pharmaceutical Industries INC. | $16.95 | 2025 | |
| Rigel Pharmaceuticals, INC. | $16.88 | 2019 | |
| Emd Serono, INC. | $16.68 | 2021 | |
| Incyte Corporation | $16.15 | 2024 | Jakafi |
| Seagen INC. | $16.12 | 2021 | |
| Astellas Pharma US INC | $14.42 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.61 | 2020 | |
| Foundation Medicine, INC. | $12.85 | 2023 | |
| Genentech USA, INC. | $12.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Sales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.